Sean T Glenn
Overview
Explore the profile of Sean T Glenn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1057
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alharbi M, Bawek S, Lund I, Glenn S, Green S, Hassan H, et al.
Ann Hematol
. 2025 Feb;
PMID: 39969535
Pure red cell aplasia (PRCA) is a rare hematological disorder characterized by erythroid hypoplasia and maturation arrest in the bone marrow. We present a case of acquired PRCA secondary to...
2.
Miyashita H, Bevins N, Thangathurai K, Lee S, Pabla S, Nesline M, et al.
Am J Cancer Res
. 2024 Jun;
14(5):2240-2252.
PMID: 38859855
Transcriptomic expression profiles of immune checkpoint markers are of interest in order to decipher the mechanisms of immunotherapy response and resistance. Overall, 514 patients with various solid tumors were retrospectively...
3.
Qian Y, Wang E, Sait S, Glenn S
Cancer Genet
. 2023 Aug;
278-279:50-54.
PMID: 37597337
We report a case of a 20-year-old man who presented with splenomegaly, hyperleukocytosis, anemia, and thrombocytopenia. A diagnosis of acute myeloid leukemia (AML) with LRRFIP1::FGFR1 rearrangement with complex karyotype was...
4.
Miyashita H, Kurzrock R, Bevins N, Thangathurai K, Lee S, Pabla S, et al.
NPJ Genom Med
. 2023 Aug;
8(1):19.
PMID: 37553332
Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging...
5.
Martinez-Gutierrez L, Burgher B, Glynias M, Alvarado D, Griffiths E, Glenn S, et al.
Cold Spring Harb Mol Case Stud
. 2023 Jul;
9(3).
PMID: 37433680
Acute myeloid leukemias (AMLs) frequently harbor activating mutations in (). The use of FLT3 inhibitors (FLT3i) is the standard of care for treatment of newly diagnosed and relapsed patients with...
6.
Glenn S, Galbo Jr P, Luce J, Miles K, Singh P, Glynias M, et al.
Oncotarget
. 2023 May;
14:450-461.
PMID: 37171376
B and T cells undergo random recombination of the VH/DH/JH portions of the immunoglobulin loci (B cell) and T-cell receptors before becoming functional cells. When one V-J rearrangement is over-represented...
7.
Brown L, Zhu J, Desai K, Kinsey E, Kao C, Lee Y, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36252996
Background: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will...
8.
Merz M, Hu Q, Merz A, Wang J, Hutson N, Rondeau C, et al.
Blood Adv
. 2022 Jul;
7(5):718-733.
PMID: 35868022
Spatial heterogeneity is a common phenomenon in metastatic solid tumors and an evolving concept in multiple myeloma (MM). The interplay between malignant plasma cells (PCs) and the microenvironment has not...
9.
Merz M, Merz A, Wang J, Wei L, Hu Q, Hutson N, et al.
Nat Commun
. 2022 Feb;
13(1):807.
PMID: 35145077
Osteolytic lesions (OL) characterize symptomatic multiple myeloma. The mechanisms of how malignant plasma cells (PC) cause OL in one region while others show no signs of bone destruction despite subtotal...
10.
Conroy J, Pabla S, Glenn S, Seager R, Van Roey E, Gao S, et al.
PLoS One
. 2021 Dec;
16(12):e0260089.
PMID: 34855780
Timely and accurate identification of molecular alterations in solid tumors is essential for proper management of patients with advanced cancers. This has created a need for rapid, scalable comprehensive genomic...